Globeflex Capital’s Tvardi Therapeutics TVRD Stock Holding History

Globeflex Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-2	Closed	-$1K	–	671
2014 Q2	$1K	Buy	+2	New	+$1.08K	﹤0.01%	534

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Globeflex Capital's TVRD Position: Q3 2014 in Review

Globeflex Capital sold out of Tvardi Therapeutics (TVRD) in Q3 2014, closing a stake of 2 shares — an estimated $1K sold.

Globeflex Capital first reported a position in TVRD in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 56 funds tracked by Wall St. Rank hold TVRD as of Q3 2014.

Globeflex Capital reported no remaining Tvardi Therapeutics position as of Q3 2014 after selling out during the quarter.
Globeflex Capital sold 2 Tvardi Therapeutics shares in Q3 2014, an estimated $1K.
Globeflex Capital first reported a position in Tvardi Therapeutics in Q2 2014 and held it in 1 quarter.
Globeflex Capital's Tvardi Therapeutics position peaked at $1K in Q2 2014.
56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2014.

Based on Globeflex Capital's 13F filing for Q3 2014, filed 15 Oct 2014.